Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
341-360 of 936 trials

Advanced Non-Small Cell Lung Cancer: BNT116 Treatment

We are evaluating the safety and early effectiveness of BNT116, both alone and with other treatments, for patients with advanced non-small cell lung cancer. This study aims to find better options for managing this condition.

Advanced Non-Small Cell Lung Cancer>2 yearsSafety phase (I)OncologyPulmonology

Late-Onset Pompe Disease: SPK-3006 Infusion Study

We are testing a new intravenous treatment for adults with late-onset Pompe disease to evaluate its safety and potential benefits. This study will help us understand how well the treatment works and how it is tolerated.

Pompe Disease>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyGastroenterologyHematologyNeurology

Gastroesophageal Adenocarcinoma: MK-2870 with Pembrolizumab and Chemotherapy

We are studying a new treatment combination for patients with advanced gastroesophageal adenocarcinoma. The goal is to evaluate its safety and how well it may help manage the disease.

Gastroesophageal CancerSafety phase (I)Efficacy phase (II)6-10 visitsInvestigational MedicinesOncology

Advanced Solid Tumors: ABBV-400 Treatment Study

We are evaluating a new treatment for adults with advanced solid tumors to see how safe and effective it is, both alone and with another medication. This study aims to improve options for patients facing these challenging conditions.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Multiple Sclerosis: RO7121932 Treatment Study

We are investigating a new treatment for people with multiple sclerosis to see how safe it is and how well it works when given in different ways. This study will help us understand its effects on the immune system and overall health.

Multiple Sclerosis>2 yearsSafety phase (I)Neurology

Multiple Myeloma: CC-92480 Combination Study

We are exploring a new treatment combination for people with relapsed or refractory multiple myeloma. The study aims to assess safety and how well it works compared to standard treatments.

Relapsed or Refractory Multiple MyelomaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

X-linked Hypophosphatemia: KK8123 Treatment Study

We are testing a new treatment called KK8123 in adults with X-linked hypophosphatemia to see if it is safe and how it affects phosphorus levels in the body.

X-linked HypophosphatemiaSafety phase (I)No PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyInternal Medicine

Frontotemporal Dementia: AVB-101 Treatment Study

We are testing a new treatment called AVB-101 for individuals with frontotemporal dementia due to specific genetic mutations. The study aims to assess its safety and early effects on symptoms.

Frontotemporal Dementia>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementNeurology

Metastatic FAP-Positive Solid Tumors: [177Lu]Lu-OncoFAP-23

We are testing a new radioactive treatment for patients with metastatic FAP-positive solid tumors. The study looks at its safety and early signs of effectiveness, both alone and with another therapy.

Advanced FAP-positive TumorsSafety phase (I)Oncology

LB-208 for Relapsed Solid Tumors and Lymphoma

We are testing a new medication for adults with solid tumors or lymphoma that have not responded to other treatments. This study aims to evaluate its safety and potential effectiveness.

LymphomaSolid Tumor>2 yearsSafety phase (I)Oncology

Primary Progressive Multiple Sclerosis: Adipose Stem Cell Treatment

We are exploring the use of stem cells from fat tissue to treat primary progressive multiple sclerosis. This study aims to assess the safety and potential benefits of this new approach.

Primary Progressive Multiple SclerosisSafety phase (I)Neurology

Autoimmune Diseases: Ublituximab Administration Study

We are evaluating how well ublituximab works when given through an IV or as a subcutaneous injection in patients with autoimmune diseases. This study aims to understand the drug's effects and how it moves through the body.

Relapsing Multiple SclerosisMyasthenia Gravis1-2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineNeurology

HER2+ Cancer Treatment: Zongertinib Study

We are exploring the safety and effectiveness of zongertinib, alone and with other treatments, for patients with advanced HER2+ metastatic breast and gastric cancers. This study aims to find the best dose and understand how it may help manage these cancers.

Gastroesophageal Junction AdenocarcinomaEsophageal AdenocarcinomaMetastatic Breast CancerSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyOncology

RAS G12C-Mutated Non-Small Cell Lung Cancer: RMC-6291 Study

We are studying a new treatment combining RMC-6291 with pembrolizumab and other therapies for patients with RAS G12C-mutated lung cancer. The goal is to evaluate safety and early signs of effectiveness.

Non-small Cell Lung CancerSafety phase (I)No PlaceboInvestigational MedicinesOncologyPulmonology

Non-Small Cell Lung Cancer: RMC-6236 with Pembrolizumab

We are studying a new treatment combining RMC-6236 and pembrolizumab for patients with advanced RAS-mutated non-small cell lung cancer. The goal is to evaluate its safety and potential effectiveness, with or without chemotherapy.

Non-small Cell Lung CancerSafety phase (I)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

MEPENDAX: Axitinib and Etoposide for Pediatric Brain Tumors

We are studying a new treatment combining axitinib and oral etoposide for children and young adults with relapsing medulloblastoma or ependymoma. The goal is to find the safest dose and see if it helps improve survival.

MedulloblastomaEpendymoma>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesNeurologyOncologyPediatrics

Alzheimer's Disease: Efavirenz Study

We are investigating whether Efavirenz can affect certain biomarkers in people with early Alzheimer's Disease. This study aims to understand its safety and how it works in the body.

Alzheimer's Disease3-6 monthsSafety phase (I)Efficacy phase (II)Standard MedicinesNeurology

Peyronie's Disease: Study of Bacterial Collagenase

We are testing a new bacterial collagenase injection for men with Peyronie's Disease to see if it improves penile curvature and reduces discomfort. The study will assess both safety and effectiveness of this treatment.

Peyronie's Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesUrology

Extensive-Stage Small Cell Lung Cancer: I-DXd with Atezolizumab

We are studying a new treatment combining I-DXd and atezolizumab, with or without carboplatin, for patients with extensive-stage small cell lung cancer. The trial aims to assess safety and effectiveness as a first-line treatment.

Extensive-stage Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Recurrent or Metastatic Solid Tumors: I-DXd Treatment Study

We are testing a new treatment called I-DXd for patients with recurrent or metastatic solid tumors. The study aims to see how well it works and how safe it is for participants.

Recurrent or Metastatic Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology